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Arnost Fronek, MD, PHD
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Objectives This study sought to assess the prognosis of subclavian stenosis (SS) as a potential marker of total and cardio-
vascular disease (CVD) mortality.
Background Subclavian stenosis, diagnosed by a brachial systolic pressure difference (BSPD) 15 mm Hg, is associated with
an increased prevalence of CVD risk factors. However, the association between SS and mortality is unknown. We
hypothesized that a BSPD 15 mm Hg would predict an increased risk of CVD events.
Methods We analyzed baseline and longitudinal data from 3 cohorts. Two were recruited from noninvasive vascular labo-
ratories, and the third was a community-dwelling cohort. Multivariate survival models were used to test for an
independent association of SS with total and CVD mortality.
Results Baseline and follow-up data (mean 9.8 years) were complete in 1,778 participants. Subclavian stenosis was
found in 157 (8.8%) subjects. Adjusted for age, gender, ethnicity, and cohort of origin, the presence of SS was
significantly associated with increased total and CVD mortality (respectively, hazard ratio [HR] 1.42, p  0.005;
and HR 1.50, p  0.05). This association persisted after adjustments for CVD risk factors (smoking pack-years,
hypertension, diabetes, total/high-density lipoprotein cholesterol ratio, and body mass index) as well as lipid-
lowering and antiplatelet therapies (HR 1.40, p  0.01; and HR 1.57, p  0.05 for total and CVD mortality, respec-
tively). When any history of CVD or an ankle-brachial index0.90 were added to the model, SS remained an indepen-
dent predictor for total mortality (HR 1.34, p 0.02), with a similar trend for CVD mortality (HR 1.43, p 0.09).
Conclusions The presence of SS, easily diagnosed by comparing systolic pressures in the left and right arm, predicts total
and CVD mortality independent of both CVD risk factors and existent CVD at baseline. (J Am Coll Cardiol 2007;
49:1540–5) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.055s
c
e
(
T
s
(
o
[
[
a
p
b
a
o

(n daily clinical practice, the measurement of systolic blood
ressure (SBP) in both arms is recommended for screening
or hypertension (1,2). This is to avoid a misdiagnosis in the
ase of lower SBP in 1 arm. This may typically occur in case
f subclavian stenosis (SS), mostly because of atherosclerotic
esions occurring proximally, including lesions of the in-
ominate artery on the right side.
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ccepted September 29, 2006.Except for the upper limb ischemia, few other clinical
ituations require the comparison of both arms’ SBPs. In
ase of dizziness or syncope, especially occurring during arm
xertion, a significant brachial systolic pressure difference
BSPD) might reflect the subclavian steal syndrome (3).
he presence of a BSPD in the context of acute chest pain
hould lead one to consider the diagnosis of aortic dissection
4). A BSPD might also be present in case of different types
f vasculitis (e.g., Takayasu disease or giant cell arteritis
5]), congenital malformations (e.g., coarctation of the aorta
6]), as well as in thoracic outlet syndrome (7), and sequelae
fter radiation therapy (8).
Notably, these cases are quite uncommon in daily general
ractice, and the observation of an asymmetric SBP between
oth arms does not routinely lead to any specific medical
ttention other than monitoring the patient’s blood pressure
n the arm with the highest blood pressure (1,2).
Based on angiographic data as the gold standard, a BSPD
15 mm Hg is highly (90%) specific for diagnosing SS
9,10). Surprisingly, although SS is mostly related to ath-
rosclerosis (11), it had not received as much attention as
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April 10, 2007:1540–5 Subclavian Stenosis and Mortalityther patterns of atherosclerosis affecting coronary, carotid,
r lower-extremity arteries. Only recently, 2 epidemiologic
tudies (12,13) reported a significant correlation between SS
nd major cardiovascular risk factors such as age, smoking,
nd dyslipidemia. In contrast to the extensive data for
eripheral arterial disease (PAD) in lower limbs and inci-
ent cardiovascular disease (CVD) events (14,15), the
rognostic value of SS, used as a marker of atherosclerotic
rocess, has never been assessed.
In this longitudinal study combining data from 3 cohorts,
e sought to assess the prognostic significance of SS for
otal and cardiovascular mortality. We hypothesized that
he presence of a BSPD15 mm Hg used for the diagnosis
f SS is associated with increased total and CVD mortality
nd could then be considered as a cardiovascular prognostic
arker.
ethods
e studied baseline and follow-up data of 1,778 subjects
1,093 men and 685 women) of 1,872 individuals participating
n 3 distinct cohort studies. We excluded 94 subjects for
ncomplete data. Two (cohorts A and B) were composed of
atients assessed for PAD in medical centers, and the third
cohort C) consisted of a community-dwelling population.
ohort presentation. Cohort A was composed of 508
atients recruited between 1990 and 1994 among those seen
n the prior 10 years for noninvasive lower extremity arterial
esting at the San Diego Veterans Administration Center or
he University of California, San Diego Medical Center,
ascular laboratories (16).
Cohort B consisted of 740 patients in the WALCS
Walking and Leg Circulation Study) cohort, recruited in 3
edical centers in the Chicago area between 1998 and 2000
17). This cohort included participants identified consecu-
ively from noninvasive vascular laboratories and a large
eneral internal medicine outpatient practice. Because this
ohort was assembled with the primary goal of identifying
redictors of decline in lower-extremity functioning, exclu-
ion criteria were wheelchair-bound patients, those with leg
mputations, nursing home residents, non–English-
peaking people, and those with dementia. Additionally,
hose with an ankle-brachial index (ABI) 1.50 were
xcluded because of the inability to provide accurate ABI
alues because of noncompressible leg arteries.
Cohort C was composed of 624 individuals participating
n the Lipid Research Clinics protocol between 1978 and
979 (18). They were initially recruited through postal and
elephone contacts. These subjects were predominantly
hite and from an upper-middle-class community in south-
rn California.
The enrollees of the 3 cohorts gave written informed
onsent for their participation in the studies. The institution
eview boards of the University of California, San Diego
cohorts A and C), and of Northwestern University and fatholic Health Partners Hospi-
al (cohort B) approved the study
rotocols.
lood pressure and ABI mea-
urement. Among the 3 co-
orts, the protocols for upper
nd lower limbs SBP measure-
ents were somewhat different
ut comparable. Briefly, the par-
icipants in cohorts A and C had
equential measurements of bra-
hial and ankle pressures, using
2-cm pneumatic cuffs and ei-
her a photoplethysmographic
ensor attached to the great toe (cohort A) or a mercury-
n-Silastic gauge (cohort C). In these 2 cohorts, arms
ressures and then ankles pressures were simultaneously
easured twice. The pressure at the site of the cuff was the
ressure measured. In these 2 cohorts, the ABI in each leg
as calculated by dividing the highest of both ankles’
ystolic pressures by the highest pressure between both
rms. In cohort B, the limbs systolic pressures were mea-
ured sequentially using a hand-held Doppler probe (Pocket
op II, Nicolet Vascular, Golden, Colorado). Each site had
sequential measurements taken. In the first set, the
equence of BP measurement was the right arm, right ankle,
eft ankle, left arm, whereas the reverse sequence was
erformed during the second set of measurements. The ABI
or each leg was calculated by dividing the highest average
eg artery systolic pressure (either posterior tibial or dorsalis
edis arteries) by the highest average SBP between both
rms. For the estimation of BSPD, the absolute values of
he difference between both arms were used. In cohort B,
he BSPD was obtained by subtracting the average SBPs of
ne arm from those of the other.
Because SBPs recorded in cohort C were rounded to the
earest 5 mm Hg, we similarly rounded cohorts A and B
BP results for analysis uniformity.
ata definition. Patient’s ethnicity was self-reported. We
lassified participants as non-Hispanic white, black, His-
anic, and others. Hypertension was defined according to
atient’s history or use of antihypertensive therapy. Patients
ere classified as diabetic according to patient’s history or
se of oral antidiabetic drugs and/or insulin. Clinical CVD
ncluded any personal history of myocardial infarction,
troke, transient ischemic attack, or revascularization of the
oronary, carotid, or lower-extremity arteries. In addition,
ubjects were considered to have clinical CVD if the ABI
as 0.90.
We defined SS by a BSPD 15 mm Hg, according to a
revious angiographic study suggesting that this threshold is
ighly specific (90%) for SS diagnosis (9,10). Additionally,
prior cross-sectional study including these 3 cohorts (13)
sed a similar threshold and showed a significant relation-
hip between BSPD 15 mm Hg and several CVD risk
Abbreviations
and Acronyms
ABI  ankle-brachial index
BSPD  brachial systolic
pressure difference
CVD  cardiovascular
disease
PAD  peripheral arterial
disease
SBP  systolic blood
pressure
SS  subclavian stenosisactors as well as PAD. To assess whether SS severity would
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Subclavian Stenosis and Mortality April 10, 2007:1540–5orrelate with poorer prognosis, we secondarily classified
articipants’ SS into moderate (15  BSPD 25 mm Hg)
r severe SS (BSPD 25 mm Hg).
ollow-up. COHORT A. Follow-up data in this cohort were
ecorded until the end of 2002 by identifying fatal events
hrough Social Security Administration data. Based on
eath certificates from the state vital statistics offices, cause
f death was adjudicated and coded by a certified nosologist.
OHORT B. Follow-up data in this cohort were recorded
hrough the end of 2003 by identifying fatal events through
ocial Security Administration data. Death certificates were
btained from the State of Illinois and from participants’
edical records. Causes of death were adjudicated by a
ertified nosologist.
OHORT C. The participants were surveyed annually to
scertain fatal events. Reported deaths were confirmed by
eath certificates, and their causes were adjudicated by a
ertified nosologist. Follow-up in this cohort was done
hrough the end of October 2002.
tatistical methods. The chi-square test was used for the
omparison of SS rates in both genders. Survival curves are
resented according to the Kaplan-Meier method, using
og-rank tests for statistical significance. For total and CVD
ortality, for each cohort as well as for the whole popula-
ion study, the predictive value of SS for total and CVD
ortality was assessed in 3 successive models using the Cox
urvival analysis. In the first model, SS hazard ratios were
djusted for age and gender. For the whole study popula-
ion, ethnicity and the cohort of origin were next added in
Description of the 3 Cohorts and the Overall Stu
Table 1 Description of the 3 Cohorts and th
Cohort A
(n  505
Baseline
Age (yrs) 68.5 (9.1)
Male gender 445 (88.1
Ethnicity
Non-Hispanic white 439 (86.9
Black 23 (4.6%
Hispanic 27 (5.3%
Other 16 (3.2%
Body mass index (kg/m2) 27.3 (8.0)
Total/high-density lipoprotein cholesterol 4.9 (1.7)
Hypertension 267 (52.3
Smoking pack-yrs 48.6 (41.6
Diabetes 156 (30.9
Lipid-lowering therapy 107 (21.2
Antiplatelet therapy 349 (69.1
Clinical cardiovascular disease 338 (66.9
ABI0.90 286 (56.6
Subclavian stenosis 26 (5.2%
Follow-up
Mean duration (yrs) 7.0 (3.2)
Total mortality 305 (60.4
Cardiovascular disease mortality 175 (34.7ABI  ankle-brachial index.his model. In model 2, CVD risk factors (smoking pack-
ears, total/high-density lipoprotein cholesterol ratio, his-
ory of diabetes, history of hypertension) as well as lipid-
owering and antiplatelet therapies were added to those
lready present in model 1. Finally, the presence of any
VD was also added in model 3. These successive models
ere used to present a stepwise control of confounding
ariables (e.g., CVD risk factors). There were no significant
nteractions between cohort and any other covariates for SS.
Because the follow-up duration varied significantly
mong the 3 cohorts, a second set of analyses was per-
ormed, limiting the follow-up data to 7 years. This
ollow-up delay was chosen regarding to the maximal length
f the follow-up period recorded in cohort B, which had the
hortest mean follow-up duration.
For all tests used, a value of p  0.05 was required for
tatistical significance. Results with a value of p  0.05 but
0.10 were considered borderline. Data were analyzed
sing Statview 5.0 (SAS Institute Inc., Cary, North Caro-
ina) statistical software.
ole of funding source. The funding organizations played
o role in the data collection, study design, data interpre-
ation and analyses, or manuscript writing.
esults
emographic, risk factor, and mortality data for the 3
ohorts and the overall population study are presented in
able 1. Overall, SS was present in 157 subjects (8.8%),
opulation
rall Study Population
Cohort B
(n  662)
Cohort C
(n  611)
Study Population
(n  1,778)
70.8 (8.4) 66.4 (10.3) 68.6 (9.5)
372 (56.2%) 276 (45.2%) 1,093 (61.5%)
518 (78.2%) 600 (98.2%) 1,557 (88.2%)
114 (17.2%) 0 (0%) 137 (7.8%)
9 (1.4%) 0 (0%) 36 (2.0%)
21 (3.2%) 11 (1.8%) 35 (2.0%)
27.8 (5.4) 24.8 (3.8) 26.6 (5.9)
4.8 (1.8) 4.1 (1.7) 4.6 (1.7)
542 (81.9%) 44 (7.2%) 853 (48.0%)
32.2 (33.9) 18.3 (25.4) 32.1 (35.8)
185 (28.0%) 22 (3.6%) 363 (20.4%)
270 (40.8%) 9 (1.5%) 386 (21.7%)
385 (58.2%) 55 (9.0%) 789 (44.4%)
363 (54.8%) 72 (11.8%) 773 (43.5%)
399 (60.3%) 87 (14.2%) 772 (43.4%)
89 (13.4%) 42 (6.9%) 157 (8.8%)
4.8 (1.6) 16.4 (6.7) 9.4 (6.8)
167 (25.2%) 374 (61.2%) 846 (47.6%)
50 (7.6%) 74 (12.1%) 299 (16.8%)dy P
e Ove
)
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April 10, 2007:1540–5 Subclavian Stenosis and Mortalityore frequent among women than men (11.2% vs. 7.3%,
 0.006).
The mean follow-up period of the entire study population
as at 9.4  6.8 years, with a maximal follow-up duration
f 11.4, 6.9, and 24.9 years for cohorts A, B, and C,
espectively. During this period, 272 (39.7%) women and
74 (52.6%) men died, including respectively 56 (8.2%) and
43 (22.2%) CVD deaths.
Figure 1 shows the overall survival curves of the entire
tudy population stratified by gender, according to the
resence or absence of SS. In both genders, survival rates
ere lower in the presence of SS. The 7-year survival is
hown according to age groups (older or younger than 70
ears) and presence of SS in Figure 2. Similar to younger
articipants, those in the elderly group had a poorer prog-
osis in the presence of SS.
Figure 3 presents the 7-year survival curves according to
he presence or absence of SS in those with and without any
VD (clinical CVD and/or ABI 0.90). Irrespective of
VD prevalence at baseline, those with an SS presented a
ignificantly poorer prognosis. A similar trend (p  0.08)
as found for the 25-year survival analysis (data not shown).
Figure 1 25-Year Survival According
to Gender and Presence of SS
SS  subclavian stenosis.
Figure 2 7-Year Survival According
to Age Group and Presence of SS
SS  subclavian stenosis.Figure 4 shows the 7-year survival curves of the partici-
ants classified in 3 categories: no SS, moderate SS, and
evere SS. The overall mortality was gradually worse with
ncreasing BSPD categories. Similar significant (p  0.001)
esults were found with the 25-year survival analysis.
Table 2 presents the adjusted hazard ratios of SS for total
nd CVD mortality in the 3 cohorts and the whole
opulation. In the fully adjusted model, a 34% excess total
ortality rate was noted in those with SS (p  0.02),
hereas there was a borderline (p  0.09) 43% CVD
ortality excess rate. The results obtained when follow-up
as limited to 7 years showed similar trends. For the whole
opulation, the fully adjusted hazard ratios for SS for the
-year total and CVD mortality were at 1.50 (p 0.01) and
.49 (p  0.12), respectively.
Because a consistent BSPD might lead to missing the
iagnosis of hypertension if only one arm’s SBP is moni-
ored, one might consider that our results could be related to
ntreated hypertension rather than an actual predictive
alue for SS. Indeed, among those with SS, 16% presented
Figure 3 7-Year Survival According to
Presence of Any CVD and Presence of SS
Any cardiovascular disease (CVD) represents clinical CVD
and/or an ankle-brachial index (ABI) 0.90. SS  subclavian stenosis.
Figure 4 7-Year Survival According to SS Severity
SS  subclavian stenosis.
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Subclavian Stenosis and Mortality April 10, 2007:1540–5n elevated (160 mm Hg) SBP without reported or
reated hypertension, compared with 7% among those
ithout SS (p  0.001). Although we consider all these
ubjects as undiagnosed hypertension (although some might
resent the “white coat” effect), the introduction of an
undiagnosed hypertension” as an independent variable in
ur predictive models did not affect hazard ratios and p
alues of SS, neither for total nor CVD mortality (data not
hown). In addition, no significant interaction between the
resence of SS and undiagnosed hypertension was found.
iscussion
hese results confirm our hypothesis on the predictive value
f a brachial systolic pressure asymmetry exceeding 15 mm
g, commonly used for defining SS in epidemiologic
tudies.
To our knowledge, this is the first study showing that,
imilar ABI as a marker of PAD, a significant BSPD can
ot only be used for the detection of SS, but also is useful as
prognostic marker. The survival of those with SS was
imilarly affected in the elderly and younger subjects, as well
s in those with and without CVD. We also found that the
egree of blood pressure asymmetry between both arms was
roportional to mortality.
Subclavian stenosis was present in almost 9% of our
articipants. This prevalence is estimated at 1.9% in a
ommunity-dwelling population (2.7% after 70 years) (13).
n another population study with a 10-mm Hg threshold,
he prevalence of abnormal inter-arm SBP difference was at
.3% (12). The prevalence of SS is higher in primary care
19) and in hospital (20) patients. By combining 2 vascular
aboratory cohorts with a general population cohort, we
nriched the sample with SS and increased study power.
able 2 shows no evidence of heterogeneity in hazard ratios
cross cohorts, indicating the appropriateness of combining
ohorts.
Subclavian stenosis is essentially related to atherosclero-
is, because other etiologies such as inflammatory diseases,
raumatic, or congenital causes compose 5% of cases in
aboratory series (11). In a cross-sectional study including
ur 3 cohorts and another free-living population cohort, a
ignificant association between SS and age, smoking, high-
ensity lipoprotein cholesterol, and the presence of PAD has
djusted Hazard Ratios (and 95% Confidence Intervals) of SSBSPD >15) for Total and CVD Mortality (M a Follow-Up 9.4 yrs)
Table 2 Adjusted Hazard Ratios (and 95% Confidence Intervals(BSPD >15) for Total and CVD Mortality (Mean Follow
Mortality
Cohort A Cohort B
Total CVD Total CVD
Model 1 1.38 (0.84–2.25) 1.26 (0.64–2.48) 1.77* (1.21–2.60) 1.52 (0.74
Model 2 1.48 (0.88–2.47) 1.48 (0.75–2.93) 1.71* (1.09–2.67) 1.50 (0.66
Model 3 1.36 (0.81–2.27) 1.31 (0.66–2.60) 1.70* (1.09–2.66) 1.45 (0.63
odel 1: adjusted for age and gender (plus ethnicity and cohort for the overall population study
ipid-lowering therapy, history of diabetes, history of hypertension, body mass index, and antipla
ignificant interaction between any cohort and SS has been noticed.
ABI  ankle-brachial index; BSPD  brachial systolic pressure difference; CVD  cardiovasculaeen reported (13). In the Ohasama population study (12), typertension, obesity, hypercholesterolemia, diabetes, and low
1.0) ABI were independent predictive factors for a BSPD
10 mm Hg. In another study on 610 patients of an
mergency department, Singer and Hollander (21) found an
nter-arm systolic or diastolic difference of more than 20
m Hg in 19% of cases, with no relation with age, gender,
r CV risk factors, but a significantly higher prevalence of
nown coronary heart disease.
According both to the seventh report of the Joint Na-
ional Committee on Prevention, Detection, Evaluation,
nd Treatment of High Blood Pressure (JNC VII) (1) and
he European Society of Hypertension/European Society of
ardiology guidelines (2), blood pressure should be mea-
ured in both arms. Unfortunately, these recommendations
re not fully respected. In a survey led in the United
ingdom (22), even general practitioners and nurses with an
nterest in hypertension did not use both arms. Our findings
n this study indicate the importance of systematic bilateral
easurement of arm blood pressure, not only to avoid
issing a hypertension diagnosis, but also to detect easily a
ypically asymptomatic atherosclerotic disease.
A major finding in our analysis is that similar to other
ascular markers (e.g., ABI), the predictive value of SS is
ndependent from the presence of traditional risk factors.
dditionally, the association with mortality remained sig-
ificant even after including data on CVD history and ABI
easurement (with borderline results for CVD death).
hus, along with the measurement of ABI, the detection of
S can also be helpful for the estimation of one’s CVD
rognosis. The comparison of arm SBP for the detection of
S has the major advantage of its feasibility in the physi-
ian’s office (15). However, this should not be substituted
or the ABI measurement, which is of well-documented
mportance (15). Our results here show that SS detection
ight provide additional information to ABI, and its
resence (irrespective of the ABI) might be considered as a
linical alert sign, with prognostic implications. Similar to
AD, it is plausible that the association between SS and
ortality be related to higher rates of concomitant unknown
therosclerotic diseases in other territories, as shown in the
tudy by Shadman et al. (13). The detection of an SS might
e considered a finding requiring more aggressive risk factor
odification, although there are no published randomized
S
.4 yrs)
Cohort C Overall*
Total CVD Total CVD
) 1.28 (0.87–1.90) 1.97 (0.94–4.12) 1.42* (1.12–1.80) 1.50* (1.00–2.52)
) 1.14 (0.76–1.70) 2.09 (0.97–4.84) 1.40* (1.09–1.80) 1.57* (1.03–2.40)
) 1.10 (0.74–1.65) 2.00 (0.93–4.33) 1.34* (1.04–1.73) 1.43 (0.93–2.18)
l 2: adjusted as Model 1  smoking pack-years, total/high-density lipoprotein cholesterol ratio,
erapy. Model 3: adjusted as Model 2  any CVD (history of clinical CVD and/or ABI 0.9). *No
se; SS  subclavian stenosis.) of S
-Up 9
–3.16
–3.41
–3.30
). Mode
telet thrial data on this question. Other studies, especially in
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April 10, 2007:1540–5 Subclavian Stenosis and Mortalityeneral practice, are required to confirm our data and to
ighlight the respective roles of ABI and BSPD measure-
ents in the prognosis determination.
tudy limitations. Our study has some limitations. First,
ounding SBP results might have affected our ability to
etect some borderline cases of SS, but this would not be a
ystematic bias. Second, the measurements were not per-
ormed simultaneously, and the BSPD measured can par-
ially be affected by the beat-to-beat variation. However, in
series of 447 hospitalized patients, Harrison et al. (23)
ound a mean right minus left SBP at 2 mm Hg when
easured sequentially versus 0.5 when measured simulta-
eously. In another series of 237 subjects primary care,
assidy and Jones (19) found a mean difference of 4.8 mm
g between the right and left SBP, compared with 2.9-mm
g differences between a first and second measurement on
he same side. Overall, the difference related to the sequen-
ial SBP measurement is substantially below the 15-mm Hg
SPD threshold used to define SS. In addition, blood
ressure is usually measured sequentially, and from a prac-
ical point of view, our findings can be applied in daily
ractice. Finally, because the detection of SS was based on
he comparison of arm SBPs, we were not able to detect
ilateral SS. Although this situation is much less common
han unilateral SS, we might have erroneously classified
ome cases of bilateral SS in the normal group, and this
ould have reduced the association between SS and mor-
ality observed here. Likewise, a BSPD 15 mm Hg is
ighly specific but poorly sensitive (50%) for SS diagnosis
9,10). Additional prospective studies are required in the
eneral population to confirm our findings.
onclusions
n this longitudinal study composed of 3 cohorts, we
ighlight the vital prognostic information provided by the
iagnosis of SS, easily identified by arm SBP asymmetry.
he presence of a BSPD 15 mm Hg is a marker for
ignificantly reduced survival. Further prospective studies in
rimary care are needed to assess the magnitude and
onsequences of our findings in clinical practice.
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